Antiretroviral Therapy Perspective

• CROI 2020 Read clinically focused news coverage of key developments from CROI 2020
  Medscape HIV/AIDS, March 06, 2020
• Infectious Diseases in 2020: 5 Areas of Concern   Dr Paul Auwaerter discusses advances made in infectious diseases in 2019 and looks ahead at concerns for the new year.
  Medscape Infectious Diseases, January 14, 2020
• Time to Rethink Renal Dosing of Lamivudine?   Dose reductions of lamivudine may not be necessary for all patients with mild to moderate renal impairment, says Dr Paul Sax.
  Medscape HIV/AIDS, November 18, 2019
• ANAC 2019 Read clinically focused news coverage of key developments from ANAC 2019
  Medscape Nurses, November 04, 2019
• USCA 2019 Read clinically focused news coverage of key developments from UCSA 2019
  Medscape HIV/AIDS, September 03, 2019
• Exploiting the CCR5 Receptor: Potential Avenue for HIV Cure?   CCR5- delta 32 mutation homozygosity is associated with increased mortality but may lead to a potential cure for HIV. Is it worth the risk?
  Medscape HIV/AIDS, July 19, 2019
• IAS 2019 Read clinically focused news coverage of key developments from IAS 2019
  Medscape HIV/AIDS, July 12, 2019
• PrEP and Risk for Sexually Transmitted Infections   Dr Paul Sax shares what he thinks is most interesting and useful about the findings that STI risk is elevated in PrEP users.
  Medscape HIV/AIDS, May 03, 2019
• CROI 2019 Read clinically focused news coverage of key developments from CROI 2019
  Medscape HIV/AIDS, February 25, 2019
• Two- vs Three-Drug Initial Therapy for HIV   Dr Paul Sax describes the potential clinical implications of the GEMINI studies.
  Medscape HIV/AIDS, November 26, 2018
• A Precaution About PrEP in HIV Prevention   PrEP can reduce new HIV infections if taken as directed. So why do PrEP failures occur?
  Medscape HIV/AIDS, November 12, 2018
• Preventing HPV in Patients With HIV: New Guidelines A degree of synergism may exist between these two viruses, so prevention of HPV in patients with HIV is critical.
  Medscape HIV/AIDS, October 26, 2018
• HIV 2018 Read clinically focused news coverage of key developments from HIV Glasgow 2018.
  Medscape HIV/AIDS, October 18, 2018
• What Doravirine Offers Patients With HIV   Dr Paul Sax describes the trials that led to the approval of doravirine, which might offer some benefits to patients who can't tolerate other NNRTIs.
  Medscape HIV/AIDS, September 13, 2018
• USCA 2018 Read clinically focused news coverage of key developments from UCSA 2018.
  Medscape HIV/AIDS, August 29, 2018
• The New Single-Tablet HIV Drug: How We Might Use It   Dr Paul Sax comments on the place Symtuza? might occupy in the HIV treatment 'medicine chest.'
  Medscape HIV/AIDS, August 02, 2018
• AIDS 2018 Read clinically focused news coverage of key developments from IAS 2018.
  Medscape HIV/AIDS, June 22, 2018
• Here's What's New in the HIV Treatment Guidelines   Dr Paul Sax reports on a new recommended HIV treatment option and thanks Marty Hirsch for his skillful leadership of the guidelines working group.
  Medscape HIV/AIDS, April 20, 2018
• This Novel, 1-Month Regimen to Prevent TB Is Practice-Changing   Dr Paul Sax reports on an intriguing two-drug regimen that could become the standard of care in preventing TB.
  Medscape HIV/AIDS, March 26, 2018
• The SWORD Study: A New Two-Drug Combo for HIV   Dr Paul Sax highlights the findings of the SWORD study of dolutegravir-rilpivirine and outlines the clinical implications.
  Medscape HIV/AIDS, March 01, 2018